… the real-life experience of AF patients undergoing anticoagulation therapy. Estimating …
experience of patients taking oral anticoagulants (DOAC or VKA) for non-valvular atrial fibrillation (…

… the real-life experience with these novel oral anticoagulants. However, … the real-life clinical
experience and gives the opportunity to … For oral anticoagulation, current European guideline …

… This study surveyed the treatment experiences and … fibrillation (AF) perceive their oral
anticoagulant (OAC) therapy with either vitamin K antagonists (VKAs) or direct oral anticoagulation …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOAC) are
non‐inferior to vitamin K antagonist for stroke prevention in non‐valvular atrial fibrillation (AF) …

… A recent meta-synthesis characterized clinician’s beliefs and experiences of oral
anticoagulation in AF [56]. However, in addition to clinician’s views, this present research includes …

OBJECTIVE: Atrial fibrillation (AF) patients are prescribed oral-anticoagulant (OAC) therapy,
often warfarin, to reduce stroke risk. We explored existing qualitative evidence about patients…

… professionals’ views and experiences of atrial fibrillation and oral-anticoagulant therapy: a
… Patients’ and physicians’ experiences of atrial fibrillation consultations and anticoagulation …

… 6, all of which have retained the term non-vitamin K antagonist oral anticoagulants. … warfarin
as the oral anticoagulants of choice, particularly for the management of atrial fibrillation (AF) …

… Patients are required to report their experiences with anticoagulant therapy during the
past 4 weeks on a 5-point scale of intensity (from not at all – 1- to extremely – 5-). The ACTS …

… Non–vitamin K antagonist oral anticoagulant claims increased … The largest increases in oral
anticoagulants use and … associated with increased oral anticoagulants treatment, whereas 27…